Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer

Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines, oxaliplatin and irinotecan, anti-VEGRand anti-EGF...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Formatua: Artigo
Hizkuntza:Russo
Argitaratua: Remedium Group LLC 2020-12-01
Saila:Медицинский совет
Gaiak:
trifluridine/tipiracil
tas-102
metastatic cancer
colorectal
chemotherapy
targeted therapy
Sarrera elektronikoa:https://www.med-sovet.pro/jour/article/view/5934
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak